Rizatriptan Benzoate Orally Disintegrating Tablets 5 mg (5mg) Recall: Impurity Out of Spec
Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma…
What is the FDA recall status?
The FDA record lists this recall as terminated. This does not establish that a retained recalled product is safe to consume or use. FDA enforcement data is not a live recall-lifecycle tracker. Follow the official instructions.
Why was Rizatriptan Benzoate Orally Disintegrating Tablets recalled?
Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples.
What should I do if I have this product?
Follow the firm and FDA instructions for the affected product. Contact the recalling firm for current guidance.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare your product with the product description and available lot, UPC or model codes below from the official FDA record to check whether it is covered by this recall. If an identifier is missing or unclear, check the complete official notice or contact the firm; an incomplete match here does not establish that your product is unaffected.
Full product description
Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA, NDC 33342-093-41
Which lot codes, UPCs or models are affected?
Lot #: BRL2102A, BRL2103A, exp. date 04/2025
- Agency record number
- D-0079-2022
- Product
- Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma…
- Recalling firm
- MACLEODS PHARMA USA, INC
- Quantity
- 13,260 Blister Packs/238,680 tablets
- Distribution
- Nationwide within the United States
- Recall started
- October 18, 2021
- Report date
- November 3, 2021
- Classification
- Class III
- Status
- Terminated
- Agency
- FDA (drug)